Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Exelixis Inc (EXEL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,804,523
  • Shares Outstanding, K 295,850
  • Annual Sales, $ 191,450 K
  • Annual Income, $ -70,220 K
  • 36-Month Beta 1.89
  • Price/Sales 39.91
  • Price/Cash Flow 0.00
  • Price/Book 31.80

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.14 +9.28%
on 11/15/17
28.46 -7.31%
on 10/18/17
-1.92 (-6.78%)
since 10/17/17
3-Month
23.18 +13.80%
on 09/26/17
32.50 -18.83%
on 10/16/17
-0.50 (-1.86%)
since 08/17/17
52-Week
14.22 +85.51%
on 01/03/17
32.50 -18.83%
on 10/16/17
+9.63 (+57.49%)
since 11/17/16

Most Recent Stories

More News
Endo (ENDP) Earnings & Revenues Beat in Q3, Generics Weak

Endo (ENDP) announced better-than-expected results for the third quarter. However, weakness in the generics segment persist and will impact results.

LGND : 140.31 (-0.99%)
ENDP : 7.54 (+3.29%)
BDSI : 2.25 (unch)
EXEL : 26.38 (+2.13%)
Perrigo (PRGO) Q3 Earnings Top, 2017 View Raised, Shares Up

Perrigo (PRGO) posts better-than-expected earnings with revenues also beating estimates. The company ups its guidance, courtesy of a continued positive execution across all business segments.

LGND : 140.31 (-0.99%)
EBS : 37.77 (-1.49%)
EXEL : 26.38 (+2.13%)
PRGO : 85.89 (-1.28%)
Merrimack (MACK) Q3 Loss Narrower than Expected, Stock Up

Merrimack (MACK) reported narrower-than-expected loss in the third quarter. With no marketed product after Onivyde sale, the company is now focused on developing its pipeline candidates.

LGND : 140.31 (-0.99%)
EXEL : 26.38 (+2.13%)
ADAP : 7.88 (-1.75%)
MACK : 11.75 (+0.86%)
Pacira (PCRX) Posts Earnings in Q3, Revenues Lag Estimates

Pacira's (PCRX) earnings surpassed estimates but sales missed the same in the third quarter of 2017. The company remains focused on the label expansion of Exparel.

LGND : 140.31 (-0.99%)
EXEL : 26.38 (+2.13%)
ADAP : 7.88 (-1.75%)
PCRX : 40.25 (+1.90%)
Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q3

Catalyst Pharma (CPRX) remains focused on the development of its pipeline candidate firdapse in the third quarter of 2017.

LGND : 140.31 (-0.99%)
EXEL : 26.38 (+2.13%)
ADAP : 7.88 (-1.75%)
CPRX : 2.93 (+0.69%)
VIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down

VIVUS (VVUS) reported third-quarter results wherein it reported narrower-than- expected loss. However, Qsymia sales fell from the year-ago period.

VVUS : 0.67 (-1.47%)
RDY : 35.91 (+0.67%)
EXEL : 26.38 (+2.13%)
TEVA : 13.84 (+8.21%)
Aerie (AERI) Q3 Loss Wider Than Expected, Pipeline in Focus

Increased operating expenses mar Aerie's (AERI) Q3 performance.

AERI : 58.70 (-1.68%)
AGN : 174.88 (+0.04%)
EXEL : 26.38 (+2.13%)
PFE : 35.37 (-0.53%)
Jazz Pharmaceuticals (JAZZ) Q3 Earnings Top, 2017 View Cut

Jazz Pharmaceuticals (JAZZ) earnings beat estimates while revenues miss the same in Q3. The company also cuts its guidance due to lower-than-expected sales from Xyrem.

JAZZ : 133.87 (+0.25%)
EBS : 37.77 (-1.49%)
IMGN : 6.15 (unch)
EXEL : 26.38 (+2.13%)
Regeneron (REGN) Beats on Q3 Earnings & Sales, Shares Up

Regeneron reported impressive results in the third quarter driven by strong performance of Eylea.

BAYRY : 31.7900 (-0.05%)
EXEL : 26.38 (+2.13%)
REGN : 391.59 (-0.79%)
SNY : 44.54 (-0.25%)
Agenus (AGEN) Reports In Line Loss in Q3, Revenues Lag

Agenus (AGEN) incurred in line loss but sales missed estimates in the third quarter of 2017.

AGEN : 3.70 (-0.27%)
LGND : 140.31 (-0.99%)
EXEL : 26.38 (+2.13%)
ADAP : 7.88 (-1.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ' (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another...

See More

Key Turning Points

2nd Resistance Point 27.19
1st Resistance Point 26.78
Last Price 26.38
1st Support Level 25.71
2nd Support Level 25.05

See More

52-Week High 32.50
Last Price 26.38
Fibonacci 61.8% 25.52
Fibonacci 50% 23.36
Fibonacci 38.2% 21.20
52-Week Low 14.22

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart